HIV/AIDS Causes & Risk Factors HIV Envelope Proteins and Their Role in HIV Entry and Infectivity GP 120, GP 41, and GP 160 By Elizabeth Boskey, PhD Elizabeth Boskey, PhD Facebook LinkedIn Twitter Elizabeth Boskey, PhD, MPH, CHES, is a social worker, adjunct lecturer, and expert writer in the field of sexually transmitted diseases. Learn about our editorial process Updated on January 08, 2022 Medically reviewed by Latesha Elopre, MD, MSPH Medically reviewed by Latesha Elopre, MD, MSPH LinkedIn Latesha Elopre, MD, is a board-certified internist specializing in HIV and an assistant professor of infectious diseases at the University of Alabama at Birmingham. Learn about our Medical Expert Board Fact checked by Heather Mercer Print Ian Cuming/Ikon Images/Getty Images HIV is an enveloped virus. That makes it different from many other retroviruses. It doesn't just have a protein coat. Instead, when HIV leaves a host cell it takes part of that cell's plasma membrane with it. That bit of membrane becomes the HIV envelope. However, the HIV envelope isn't only made up of components from the host. It is also made up of HIV envelope proteins. HIV envelope proteins include gp41, gp120, and gp160. GP stands for "glycoprotein". Glycoproteins have carbohydrate, or sugar, components as well as a protein backbone. The number after the gp refers to the proteins' length. Note: Not all glycoproteins are associated with viruses. Many of the most important proteins in the immune system are also glycoproteins. So are numerous other proteins found in the human body. Protein gp120 is probably the best known of the HIV envelope proteins. Several HIV vaccines have attempted to target it. It is very important in the binding of HIV to CD4 cells. Many researchers believe that if they could effectively interfere with gp120 binding, they would be able to reduce HIV transmission. In addition to gp120, gp41 is also important in assisting HIV's entry into host cells. It helps the viral membrane and the cell membrane fuse. This is a critical part of the infection process. The fusion of the two membranes is the first step towards releasing the viral RNA into the cell for replication. In fact, the fusion inhibitor enfuvirtide actually works by interfering with gp41. Gp41 is also the protein that keeps gp120 attached to the viral envelope. It sits in the membrane and binds to gp120. Gp120 doesn't attach to the envelope directly. Gp160 isn't actually a third HIV envelope protein. Instead, gp160 is the precursor of gp120 and gp41. The larger protein, gp160, is coded for by the env (envelope) gene. It is then cut apart into two smaller pieces by enzymes in the host cell yielding gp120 and gp41. Role in HIV Entry and Infectivity HIV envelope proteins have an important role in HIV entry and infectivity. They are also potentially quite important in prevention and treatment. However, interestingly, the topic of HIV envelope proteins also often comes up in discussions of HIV testing. For example, a Western Blot isn't considered to be a definitive diagnosis for HIV unless a person has antibodies against both HIV envelope proteins and HIV core proteins. There are also concerns about how HIV vaccine trials may affect routine HIV testing. The growing number of people who have participated in these trials could lead to more false positive HIV antibody tests. Vaccines are usually designed to cause the body to make antibodies against specific proteins, such as the HIV envelope proteins. Since those antibodies are exactly what standard HIV tests look for, it could lead to a false positive. After participating in an HIV vaccine trial, it is important to get the right test going forward; one that looks for the virus itself instead of antibodies. If you do participate in an HIV vaccine trial, tell your healthcare provider and you may decide to decline standard HIV tests. You should also keep careful records of your participation in any vaccine trials. HIV Healthcare Provider Discussion Guide Get our printable guide for your next healthcare provider's appointment to help you ask the right questions. Download PDF Sign up for our Health Tip of the Day newsletter, and receive daily tips that will help you live your healthiest life. Sign Up You're in! Thank you, {{form.email}}, for signing up. There was an error. Please try again. 8 Sources Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy. Avert.org. The science of HIV and AIDS – Overview. Checkley MA, Luttge BG, Freed EO. HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. Journal of Molecular Biology. 2011;410(4):582-608. doi:10.1016/j.jmb.2011.04.042 Horiya S, MacPherson IS, Krauss IJ. Recent strategies targeting HIV glycans in vaccine design. Nat Chem Biol. 2014;10(12):990-999. doi:10.1038/nchembio.1685 Chen RY, Kilby JM, Saag MS. Enfuvirtide. Expert Opinion on Investigational Drugs. 2002;11(12):1837-1843. doi:10.1517/13543784.11.12.1837 Lu W, Chen S, Yu J, et al. The polar region of the HIV-1 envelope protein determines viral fusion and infectivity by stabilizing the gp120-gp41 association. Kirchhoff F, ed. J Virol. 2019;93(7). doi:10.1128/JVI.02128-18 Branson BM, Owen M, Wesolowski LG, Bennett B, et al. Laboratory testing for the diagnosis of HIV infection: Updated recommendations. Centers for Disease Control and Prevention; Association of Public Health Laboratories; National Center for HIV/AIDS, Viral Hepatitis, and TB Prevention, Division of HIV/AIDS Prevention. 2014. doi:10.15620/cdc.23447 Newman PA, Daley A, Halpenny R, Loutfy M. Community heroes or “high-risk” pariahs? Reasons for declining to enroll in an HIV vaccine trial. Vaccine. 2008;26(8):1091-1097. doi:10.1016/j.vaccine.2007.12.016 HIV Trials Vaccine Network. Getting the right test for HIV. doi:10.1016/j.vaccine.2007.12.016 By Elizabeth Boskey, PhD Elizabeth Boskey, PhD, MPH, CHES, is a social worker, adjunct lecturer, and expert writer in the field of sexually transmitted diseases. See Our Editorial Process Meet Our Medical Expert Board Share Feedback Was this page helpful? Thanks for your feedback! What is your feedback? Other Helpful Report an Error Submit